Stryker [SYK] vs Boston Scientific [BSX] Detailed Stock Comparison
Stryker
NYSE
Loading...
Boston Scientific
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Stryker wins in 12 metrics, Boston Scientific wins in 7 metrics, with 0 ties. Stryker appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Stryker | Boston Scientific | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 52.10 | 63.82 | Stryker |
| Price-to-Book Ratio | 7.08 | 7.08 | Stryker |
| Debt-to-Equity Ratio | 80.83 | 53.09 | Boston Scientific |
| PEG Ratio | 7.54 | 0.44 | Boston Scientific |
| EV/EBITDA | 25.77 | 36.26 | Stryker |
| Profit Margin (TTM) | 12.25% | 13.55% | Boston Scientific |
| Operating Margin (TTM) | 21.95% | 18.63% | Stryker |
| EBITDA Margin (TTM) | 21.95% | 18.63% | Stryker |
| Return on Equity | 14.25% | 11.55% | Stryker |
| Return on Assets (TTM) | 7.74% | 5.39% | Stryker |
| Free Cash Flow (TTM) | $3.49B | $2.37B | Stryker |
| Dividend Yield | 0.88% | N/A | N/A |
| 1-Year Return | 9.30% | 31.40% | Boston Scientific |
| Price-to-Sales Ratio (TTM) | 6.30 | 8.59 | Stryker |
| Enterprise Value | $164.65B | $170.60B | Boston Scientific |
| EV/Revenue Ratio | 6.91 | 9.23 | Stryker |
| Gross Profit Margin (TTM) | 63.78% | 67.65% | Boston Scientific |
| Revenue per Share (TTM) | $62 | $13 | Stryker |
| Earnings per Share (Diluted) | $7.53 | $1.68 | Stryker |
| Beta (Stock Volatility) | 0.93 | 0.66 | Boston Scientific |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Stryker vs Boston Scientific Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Stryker | -0.51% | 0.23% | 3.01% | 2.40% | -0.85% | 9.36% |
| Boston Scientific | -0.07% | 1.63% | 2.28% | 4.27% | 2.40% | 19.96% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Stryker | 9.30% | 70.57% | 94.19% | 293.69% | 740.60% | 619.04% |
| Boston Scientific | 31.40% | 149.70% | 166.12% | 534.81% | 1,911.63% | 327.17% |
News Based Sentiment Overview
Stryker
News based Sentiment: positive
Key Insights:
Stryker delivered a strong Q2, exceeding expectations and reaffirming its full-year guidance. This positive performance, combined with increased institutional interest signaled by its inclusion on the RBC DS US Equity Focus List, suggests a positive trajectory for the company. While insider selling is present, the overall narrative remains optimistic.
Boston Scientific
News based Sentiment: mixed
Key Insights:
Boston Scientific delivered a strong Q2 performance and raised its full-year guidance, which is positive. However, significant insider selling and a potentially high-risk FDA issue create uncertainty and balance out the positive developments, making this a mixed month for investors.
Performance & Financial Health Analysis: Stryker vs Boston Scientific
| Metric | SYK | BSX |
|---|---|---|
| Market Information | ||
| Market Cap | $149.98B | $158.87B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 945,200 | 5,993,280 |
| 90 Day Avg. Volume | 1,214,283 | 6,094,917 |
| Last Close | $392.31 | $107.22 |
| 52 Week Range | $329.16 - $406.19 | $80.50 - $108.94 |
| % from 52W High | -3.42% | -1.58% |
| All-Time High | $406.19 (Jan 27, 2025) | $108.94 (Jul 23, 2025) |
| % from All-Time High | -3.42% | -1.58% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.11% | 0.23% |
| Quarterly Earnings Growth | 0.07% | 1.46% |
| Financial Health | ||
| Profit Margin (TTM) | 0.12% | 0.14% |
| Operating Margin (TTM) | 0.22% | 0.19% |
| Return on Equity (TTM) | 0.14% | 0.12% |
| Debt to Equity (MRQ) | 80.83 | 53.09 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $55.43 | $15.14 |
| Cash per Share (MRQ) | $6.45 | $0.36 |
| Operating Cash Flow (TTM) | $4.77B | $4.28B |
| Levered Free Cash Flow (TTM) | $3.49B | $2.94B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.88% | N/A |
| Last 12-Month Dividend | $3.28 | N/A |
Valuation & Enterprise Metrics Analysis: Stryker vs Boston Scientific
| Metric | SYK | BSX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 52.10 | 63.82 |
| Forward P/E | 29.00 | 38.43 |
| PEG Ratio | 7.54 | 0.44 |
| Price to Sales (TTM) | 6.30 | 8.59 |
| Price to Book (MRQ) | 7.08 | 7.08 |
| Market Capitalization | ||
| Market Capitalization | $149.98B | $158.87B |
| Enterprise Value | $164.65B | $170.60B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 6.91 | 9.23 |
| Enterprise to EBITDA | 25.77 | 36.26 |
| Risk & Other Metrics | ||
| Beta | 0.93 | 0.66 |
| Book Value per Share (MRQ) | $55.43 | $15.14 |
Financial Statements Comparison: Stryker vs Boston Scientific
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SYK | BSX |
|---|---|---|
| Revenue/Sales | $6.02B | $4.66B |
| Cost of Goods Sold | $2.18B | $1.45B |
| Gross Profit | $3.84B | $3.21B |
| Research & Development | $407.00M | $443.00M |
| Operating Income (EBIT) | $1.17B | $937.00M |
| EBITDA | $1.52B | $1.23B |
| Pre-Tax Income | $1.02B | $805.00M |
| Income Tax | $132.00M | $133.00M |
| Net Income (Profit) | $884.00M | $672.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SYK | BSX |
|---|---|---|
| Cash & Equivalents | $2.32B | $725.00M |
| Total Current Assets | $13.02B | $7.34B |
| Total Current Liabilities | $7.93B | $5.06B |
| Long-Term Debt | $14.38B | $10.93B |
| Total Shareholders Equity | $20.93B | $22.45B |
| Retained Earnings | $18.86B | $3.35B |
| Property, Plant & Equipment | $1.67B | $448.00M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SYK | BSX |
|---|---|---|
| Operating Cash Flow | $719.00M | $513.00M |
| Capital Expenditures | $-123.00M | $-187.00M |
| Free Cash Flow | $127.00M | $277.00M |
| Debt Repayment | N/A | $-1.31B |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SYK | BSX |
|---|---|---|
| Shares Short | 4.24M | 18.60M |
| Short Ratio | 3.20 | 2.62 |
| Short % of Float | 0.01% | 0.01% |
| Average Daily Volume (10 Day) | 945,200 | 5,993,280 |
| Average Daily Volume (90 Day) | 1,214,283 | 6,094,917 |
| Shares Outstanding | 381.40M | 1.47B |
| Float Shares | 344.60M | 1.48B |
| % Held by Insiders | 0.05% | 0.00% |
| % Held by Institutions | 0.82% | 0.94% |
Dividend Analysis & Yield Comparison: Stryker vs Boston Scientific
| Metric | SYK | BSX |
|---|---|---|
| Last 12-Month Dividend | $3.28 | N/A |
| Last 12-Month Dividend Yield | 0.88% | N/A |
| 3-Year Avg Annual Dividend | $3.09 | N/A |
| 3-Year Avg Dividend Yield | 0.27% | N/A |
| 3-Year Total Dividends | $9.26 | N/A |
| Ex-Dividend Date | Mar 31, 2025 | N/A |